The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss

Molecular Cancer Therapeutics

Volumn 9, Issue 12, 2010, Pages 3210-3220

  Pratap, Jitesh ^a   Akech, Jacqueline ^a   Wixted, John J ^a,b   Szabo, Gabriela ^c   Hussain, Sadiq ^a   McGee Lawrence, Meghan E ^d   Li, Xiaodong ^d   Bedard, Krystin ^a   Dhillon, Robinder J ^d   Van Wijnen, Andre J ^a   Stein, Janet L ^a,e   Stein, Gary S ^a,e   Westendorf, Jennifer J ^d   Lian, Jane B ^a,e  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b Departments Orthopedic Surgery   (United States)

^c Departments of Medicine   (United States)

^d MAYO CLINIC   (United States)

^e RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE; INTERLEUKIN 8; OSTEOPONTIN; PARATHYROID HORMONE RELATED PROTEIN; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MASS; BONE METASTASIS; BONE RADIOGRAPHY; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME INHIBITION; FEMUR; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSTEOLYSIS; OSTEOPENIA; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH;

ANIMALS; BONE AND BONES; BONE NEOPLASMS; BONE RESORPTION; CELL LINE, TUMOR; CELL PROLIFERATION; EXTREMITIES; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MICE; MICE, SCID; OSTEOLYSIS; TUMOR BURDEN; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78650506912     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0572     Document Type: Article

References (48)

1. Shah NL, Sanda M. Health-related quality of life in treatment for prostate cancer: Looking beyond survival. Support Cancer Ther 2004;1:230-6.
2. Mundy GR. Mechanisms of bone metastasis. Cancer 1997;80:1546-56.
3. Roodman GD. Pathogenesis of myeloma bone disease. Leukemia 2009;23:435-41.
4. Roudier MP, Morrissey C, True LD, Higano CS, Vessella RL, Ott SM. Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol 2008;180:1154-60.
5. Acharya MR, Sparreboom A, Venitz J, Figg WD. Rational development of histone deacetylase inhibitors as anticancer agents: A review. Mol Pharmacol 2005;68:917-32.
6. Hess-Stumpp H. Histone deacetylase inhibitors and cancer: From cell biology to the clinic. Eur J Cell Biol 2005;84:109-21.
7. Komatsu Y, Tomizaki KY, Tsukamoto M, Kato T, Nishino N, Sato S, et al. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. Cancer Res 2001;61:4459-66.
8. Qiu L, Burgess A, Fairlie DP, Leonard H, Parsons PG, Gabrielli BG. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell 2000;11: 2069-83.
9. Richon VM, Zhou X, Rifkind RA, Marks PA. Histone deacetylase inhibitors: Development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. Blood Cells Mol Dis 2001;27: 260-4.
10. Duvic M, Vu J. Vorinostat: A new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 2007;16:1111-20.
11. O'Connor OA. Targeting histones and proteasomes: New strategies for the treatment of lymphoma. J Clin Oncol 2005;23:6429-36.
12. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923-31.
13. Luu TH, Morgan RJ, Leong L, Lim D, McNamara M, Portnow J, et al. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: A California Cancer Consortium study. Clin Cancer Res 2008;14:7138-42.
14. Rubin EH, Agrawal NG, Friedman EJ, Scott P, Mazina KE, Sun L, et al. A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Clin Cancer Res 2006;12:7039-45.
15. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007;25:84-90.
16. Secrist JP, Zhou X, Richon VM. HDAC inhibitors for the treatment of cancer. Curr Opin Investig Drugs 2003;4:1422-7.
17. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett 2009;280:168-76.
18. Vega RB, Matsuda K, Oh J, Barbosa AC, Yang X, Meadows E, et al. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 2004;119:555-66.
19. Arnold MA, Kim Y, Czubryt MP, Phan D, McAnally J, Qi X, et al. MEF2C transcription factor controls chondrocyte hypertrophy and bone development. Dev Cell 2007;12:377-89.
20. Jensen ED, Nair AK, Westendorf JJ. Histone deacetylase co-repressor complex control of Runx2 and bone formation. Crit Rev Eukaryot Gene Expr 2007;17:187-96.
21. Chen TH, Chen WM, Hsu KH, Kuo CD, Hung SC. Sodium butyrate activates ERK to regulate differentiation of mesenchymal stem cells. Biochem Biophys Res Commun 2007;355:913-8.
22. Yi T, Baek JH, Kim HJ, Choi MH, Seo SB, Ryoo HM, et al. Trichostatin A-mediated upregulation of p21(WAF1) contributes to osteoclast apoptosis. Exp Mol Med 2007;39:213-21.
23. Huang WC, Xie Z, Konaka H, Sodek J, Zhau HE, Chung LW. Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: Role of cAMP-dependent protein kinase: A signaling pathway. Cancer Res 2005;65:2303-13.
24. Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci U S A 1996;93:5705-8.
25. Trevant B, Gaur T, Hussain S, Symons J, Komm BS, Bodine PV, et al. Expression of secreted frizzled related protein 1, a Wnt antagonist, in brain, kidney, and skeleton is dispensable for normal embryonic development. J Cell Physiol 2008;217:113-26.
26. Miao D, Scutt A. Histochemical localization of alkaline phosphatase activity in decalcified bone and cartilage. J Histochem Cytochem 2002;50:333-40.
27. He LZ, Tolentino T, Grayson P, Zhong S, Warrell Jr. RP, Rifkind RA, et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 2001;108:1321-30.
28. Redner RL, Liu JM. Leukemia fusion proteins and co-repressor complexes: Changing paradigms. J Cell Biochem 2005;94: 864-9.
29. Martinez-Iglesias O, Ruiz-Llorente L, Sanchez-Martinez R, Garcia L, Zambrano A, Aranda A. Histone deacetylase inhibitors: Mechanism of action and therapeutic use in cancer. Clin Transl Oncol 2008;10: 395-8.
30. Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 2001;61:8492-7.
31. Kumagai T, Wakimoto N, Yin D, Gery S, Kawamata N, Takai N, et al. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer 2007;121:656-65.
32. Vrana JA, Decker RH, Johnson CR,, Wang Z, Jarvis WD, Richon VM, et al. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 1999;18:7016-25.
33. Lakshmikanthan V, Kaddour-Djebbar I, Lewis RW, Kumar MV. SAHAsensitized prostate cancer cells to TNFalpha-related apoptosis-inducing ligand (TRAIL): Mechanisms leading to synergistic apoptosis. Int J Cancer 2006;119:221-8.
34. Heider U, Kaiser M, Sterz J, Zavrski I, Jakob C, Fleissner C, et al. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. Eur J Haematol 2006;76:42-50.
35. Choo QY, Ho PC, Tanaka Y, Lin HS. Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide- stimulated NF-kappaB p65 nuclear accumulation in human rheumatoid arthritis synovial fibroblastic E11 cells. Rheumatology (Oxford) 2010;49:1447-60.
36. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: Molecular mechanisms of action. Oncogene 2007;26:5541-52.
37. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and geneassociated histone acetylation. Proc Natl Acad Sci U S A 2000;97: 10014-9.
38. Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter- associated proteins, including HDAC1. Proc Natl Acad Sci U S A 2004;101:1241-6.
39. Wang S, Yan-Neale Y, Zeremski M, Cohen D. Transcription regulation by histone deacetylases. Novartis Found Symp 2004;259:238-45.
40. Lee EM, Shin S, Cha HJ, Yoon Y, Bae S, Jung JH, et al. Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells. Int J Mol Med 2009;24:45-50.
41. Schroeder TM, Westendorf JJ. Histone deacetylase inhibitors promote osteoblast maturation. J Bone Miner Res 2005;20:2254-63.
42. Schroeder TM, Kahler RA, Li X, Westendorf JJ. Histone deacetylase 3 interacts with runx2 to repress the osteocalcin promoter and regulate osteoblast differentiation. J Biol Chem 2004;279:41998-2007.
43. Cho HH, Park HT, Kim YJ, Bae YC, Suh KT, Jung JS. Induction of osteogenic differentiation of human mesenchymal stem cells by histone deacetylase inhibitors. J Cell Biochem 2005;96:533-42.
44. Richon VM, Garcia-Vargas J, Hardwick JS. Development of vorinostat: Current applications and future perspectives for cancer therapy. Cancer Lett 2009;280:201-10.
45. Sonnemann J, Bumbul B, Beck JF. Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro. Mol Cancer Ther 2007;6:2976-84.
46. Holen I, Coleman RE. Bisphosphonates as treatment of bone metastases. Curr Pharm Des 2010;16:1262-71.
47. Buijs JT, Que I, Lowik CW, Papapoulos SE, Van der Pluijm G. Inhibition of bone resorption and growth of breast cancer in the bone microenvironment. Bone 2009;44:380-6.
48. Thudi NK, Martin CK, Nadella MV, Fernandez SA, Werbeck JL, Pinzone JJ, et al. Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions. Prostate 2008;68:1116-25.